Literature DB >> 11262555

Metabolic alkalosis.

A Khanna1, N A Kurtzman.   

Abstract

Metabolic alkalosis is a primary pathophysiologic event characterized by the gain of bicarbonate or the loss of nonvolatile acid from extracellular fluid. The kidney preserves normal acid-base balance by two mechanisms: bicarbonate reclamation, mainly in the proximal tubule, and bicarbonate generation, predominantly in the distal nephron. Bicarbonate reclamation is mediated mainly by a Na(+)-H(+) antiporter and to a smaller extent by the H(+)-ATPase (adenosine triphosphate-ase). The principal factors affecting HCO3(-) reabsorption include effective arterial blood volume, glomerular filtration rate, chloride, and potassium. Bicarbonate regeneration is primarily affected by distal Na(+) delivery and reabsorption, aldosterone, arterial pH, and arterial partial pressure of carbon dioxide. To generate metabolic alkalosis, either a gain of base or a loss of acid must occur. The loss of acid may be via the gastrointestinal tract or via the kidney. Excess base may be gained by oral or parenteral HCO3(-) administration or by lactate, acetate, or citrate administration. Factors that help maintain metabolic alkalosis include decreased glomerular filtration rate, volume contraction, hypokalemia, hypochloremia, and aldosterone excess. Clinical states associated with metabolic alkalosis are vomiting, mineralocorticoid excess, the adrenogenital syndrome, licorice ingestion, diuretic administration, and Bartter's and Gitelman's syndromes. The effects of metabolic alkalosis on the body are variable and include effects on the central nervous system, myocardium, skeletal muscle, and liver. Treatment of this disorder is simple, once the pathophysiology of the cause is delineated. Therapy consists of reversing the contributory factors that are promoting the alkalosis and, in severe cases, administration of carbonic anhydrase inhibitors, acid infusion, and low bicarbonate dialysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262555

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  8 in total

1.  Use of sodium concentration and anion gap to improve correlation between serum chloride and bicarbonate concentrations.

Authors:  Mark Feldman; Nilam J Soni; Beverly Dickson
Journal:  J Clin Lab Anal       Date:  2006       Impact factor: 2.352

2.  Serum bicarbonate and mortality in stage 3 and stage 4 chronic kidney disease.

Authors:  Sankar D Navaneethan; Jesse D Schold; Susana Arrigain; Stacey E Jolly; Edgard Wehbe; Rupesh Raina; James F Simon; Titte R Srinivas; Anil Jain; Martin J Schreiber; Joseph V Nally
Journal:  Clin J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 8.237

3.  Baking soda can settle the stomach but upset the heart: case files of the Medical Toxicology Fellowship at the University of California, San Francisco.

Authors:  Suad A Al-Abri; Kent R Olson
Journal:  J Med Toxicol       Date:  2013-09

4.  Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation.

Authors:  Christophe Faisy; Amel Mokline; Olivier Sanchez; Jean-Marc Tadié; Jean-Yves Fagon
Journal:  Intensive Care Med       Date:  2010-03-09       Impact factor: 17.440

5.  Association of serum bicarbonate with risk of renal and cardiovascular outcomes in CKD: a report from the Chronic Renal Insufficiency Cohort (CRIC) study.

Authors:  Mirela Dobre; Wei Yang; Jing Chen; Paul Drawz; L Lee Hamm; Edward Horwitz; Thomas Hostetter; Bernard Jaar; Claudia M Lora; Lisa Nessel; Akinlolu Ojo; Julia Scialla; Susan Steigerwalt; Valerie Teal; Myles Wolf; Mahboob Rahman
Journal:  Am J Kidney Dis       Date:  2013-03-13       Impact factor: 8.860

Review 6.  Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit?

Authors:  Nicholas Heming; Saïk Urien; Christophe Faisy
Journal:  Crit Care       Date:  2012-08-07       Impact factor: 9.097

7.  Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients.

Authors:  Nicholas Heming; Christophe Faisy; Saïk Urien
Journal:  Crit Care       Date:  2011-09-14       Impact factor: 9.097

8.  Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients.

Authors:  Nicholas Heming; Saïk Urien; Virginie Fulda; Ferhat Meziani; Arnaud Gacouin; Marc Clavel; Benjamin Planquette; Christophe Faisy
Journal:  PLoS One       Date:  2014-01-17       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.